Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Bristol Myers Squibb reported a patient death in a Phase 1 trial for its CAR-T therapy targeting multiple sclerosis. The patient had pre-existing complications and died from septic pneumonia. The company noted this may impact the therapy's safety assessment. The incident raises concerns about CAR-T therapy's safety and regulatory challenges in autoimmune treatments.

Bristol Myers Squibb (BMY) reported a serious adverse event in its phase 1 trial for CAR-T therapy zolacabtagene autoleucel, including a patient death. Early efficacy data showed promise for multiple sclerosis treatment. The company offers a 4.02% dividend yield with a 41% payout ratio and a GF Value of $56.82, suggesting fair valuation. BMY's GF Score is 72, reflecting solid financial health.

Bristol-Myers Squibb (BMY) stock fell 2% after a patient death in an early-stage CAR T trial for multiple sclerosis. Despite this, the trial showed promising efficacy results, with all 60 higher-dose patients remaining off regular MS drugs. BMY stock is up 14% year-to-date, and retail sentiment remains bullish. According to StockTwits.

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

Bristol Myers Squibb shared interim results from its Phase 1 Breakfree-2 study of zolacabtagene autoleucel (zola-cel) in multiple sclerosis. The study included 66 patients, showing a safety profile consistent with prior data and promising efficacy. 42.4% had cytokine release syndrome, mostly Grade 1. One fatal event occurred due to septic pneumonia. All patients at dose level 2 remained off disease-modifying therapies, with some showing improved disability progression.

Bristol-Myers Squibb's shares declined after a patient death in its Phase 1 Breakfree-2 multiple sclerosis study. The company disclosed the incident, leading to a 2.02% drop in share price. The study is an early-stage cell therapy trial.